Patents by Inventor Philip Hipskind

Philip Hipskind has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9334267
    Abstract: This invention provides compounds of Formula I: (Formula I should be inserted here) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising a compound of Formula I; and use of a compound of Formula I for treating specified cancers.
    Type: Grant
    Filed: March 5, 2013
    Date of Patent: May 10, 2016
    Assignee: Deciphera Pharmaceuticals, LLC
    Inventors: Daniel L. Flynn, Michael D. Kaufman, Lakshminarayana Vogeti, Scott Wise, Wei-Ping Lu, Bryan Smith, James R. Henry, Philip A. Hipskind, Sheng-Bin Peng
  • Patent number: 9187474
    Abstract: This invention provides compounds of Formula (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising a compound of Formula (I); and use of a compound of Formula (I) for treating specified cancers.
    Type: Grant
    Filed: March 5, 2013
    Date of Patent: November 17, 2015
    Assignees: Deciphera Pharmaceuticals, LLC, Eli Lilly and Company
    Inventors: Daniel L. Flynn, Michael D. Kaufman, Lakshminarayana Vogeti, Scott Wise, Wei-Ping Lu, Bryan Smith, Timothy Malcolm Caldwell, William C. Patt, James R. Henry, Philip A. Hipskind, Sheng-Bin Peng
  • Publication number: 20150119392
    Abstract: This invention provides compounds of Formula I: (Formula I should be inserted here) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising a compound of Formula I; and use of a compound of Formula I for treating specified cancers.
    Type: Application
    Filed: March 5, 2013
    Publication date: April 30, 2015
    Inventors: Daniel L. Flynn, Michael D. Kaufman, Lakshminarayana Vogeti, Scott Wise, Wei-Ping Lu, Bryan Smith, James R. Henry, Philip A. Hipskind, Sheng-Bin Peng
  • Publication number: 20150105367
    Abstract: This invention provides compounds of Formula (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising a compound of Formula (I); and use of a compound of Formula (I) for treating specified cancers.
    Type: Application
    Filed: March 5, 2013
    Publication date: April 16, 2015
    Inventors: Daniel L. Flynn, Michael D, Kaufman, Lakshminarayana Vogeti, Scott Wise, Wei-Ping Lu, Bryan Smith, Timothy Malcolm Caldwell, William C. Patt, James R. Henry, Philip A. Hipskind, Sheng-Bin Peng
  • Publication number: 20070208024
    Abstract: The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof, which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds.
    Type: Application
    Filed: March 25, 2005
    Publication date: September 6, 2007
    Inventors: Lisa Beavers, Don Finley, Terry Finn, Robert Gadski, Philip Hipskind, William Hornback, Cynthia Jesudason, Richard Pickard, Takako Takakuwa, Grant Vaught
  • Publication number: 20070155754
    Abstract: The present invention discloses novel compounds of Formula I or pharmaceutically acceptable salts thereof which have histamine-H3 receptor antagonist activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using them to treat obesity and other histamine H3 receptor-related diseases.
    Type: Application
    Filed: February 22, 2005
    Publication date: July 5, 2007
    Inventors: Lisa Beavers, Robert Gadski, Philip Hipskind, Cynthia Jesudason, Karen Lobb, Richard Pickard, Craig Lindsley
  • Publication number: 20060223871
    Abstract: The present invention provides antineoplastic compounds of the formula: and antineoplastic methods.
    Type: Application
    Filed: June 6, 2006
    Publication date: October 5, 2006
    Inventors: Cora Grossman, Philip Hipskind, Ho-Shen Lin, Karen Lobb, Beatriz Lopez de Uralde Garmendia, Jose Lopez, Mary Mader, Michael Richett, Chuan Shih, Alfonso De Dios
  • Publication number: 20060167046
    Abstract: The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof which have histamine-II3 receptor antagonist activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I), as well as methods or using them to treat obesity and other histamine II3 receptor-related diseases.
    Type: Application
    Filed: September 12, 2003
    Publication date: July 27, 2006
    Applicant: Eli Lilly and Company Patent Division
    Inventors: Lisa Beavers, Don Finley, Robert Gadski, Philip Hipskind, Cynthia Jesudason, Richard Pickard, Freddie Stevens
  • Publication number: 20060160794
    Abstract: The present invention relates to selective NK-1 receptor antagonists of Formula (I) or a pharmaceutically acceptable salt thereof, for the treatment of disorders associated with an excess of tachykinins.
    Type: Application
    Filed: June 3, 2004
    Publication date: July 20, 2006
    Inventors: Albert Amegadzie, Kevin Gardinier, Erik Hembre, Philip Hipskind, Louis Jungheim, Brian Muehl, Kenneth Savin, Keneth Thrasher, Steven Boyd
  • Publication number: 20050272718
    Abstract: The present invention relates to a melanin concentrating hormone antagonist compound of formula I: (I); or a pharmaceutically acceptable salt, solvate, enantiomer or prodrug thereof useful in the treatment, prevention or amelioration of symptoms associated with obesity and related diseases.
    Type: Application
    Filed: May 6, 2003
    Publication date: December 8, 2005
    Inventors: Jochen Ammenn, James Gillig, Lawrence Heinz, Philip Hipskind, Michael Kinnick, Yen-Shi Lai, John Morin, James Nixon, Carsten Ott, Kenneth Savin, Theo Schotten, Lawrence Slieker, Nancy Snyder, Michael Robertson
  • Patent number: 6869957
    Abstract: This invention provides a novel series of non-peptidyl compounds which are useful in the treatment or prevention of a physiological disorder associated with an excess of tachykinins. This invention also provides methods for the treatment of such physiological disorders as well as pharmaceutical formulations which employ these novel compounds.
    Type: Grant
    Filed: September 23, 2003
    Date of Patent: March 22, 2005
    Assignee: Eli Lilly and Company
    Inventors: Sung Y. Cho, Thomas A. Crowell, Bruce D. Gitter, Philip A. Hipskind, J. Jeffry Howbert, Joseph H. Krushinski, Jr., Karen L. Lobb, Brian S. Muehl, James A. Nixon
  • Patent number: 6727255
    Abstract: This invention provides a novel series of non-peptidyl compounds which are useful in the treatment or prevention of a physiological disorder associated with an excess of tachykinins. This invention also provides methods for the treatment of such physiological disorders as well as pharmaceutical formulations which employ these novel compounds.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: April 27, 2004
    Assignee: Eli Lilly and Company
    Inventors: Sung Y. Cho, Thomas A. Crowell, Bruce D. Gitter, Philip A. Hipskind, J. Jeffry Howbert, Joseph H. Krushinski, Jr., Karen L. Lobb, Brian S. Muehl, James A. Nixon
  • Patent number: 6403577
    Abstract: This invention provides a novel series of non-peptidyl compounds which are useful in the treatment or prevention of a physiological disorder associated with an excess of tachykinins. This invention also provides methods for the treatment of such physiological disorders as well as pharmaceutical formulations which employ these novel compounds.
    Type: Grant
    Filed: November 17, 1993
    Date of Patent: June 11, 2002
    Assignee: Eli Lilly and Company
    Inventors: Sung Y. Cho, Thomas A. Crowell, Bruce D. Gitter, Philip A. Hipskind, J. Jeffry Howbert, Joseph H. Krushinski, Jr., Karen L. Lobb, Brian S. Muehl, James A. Nixon
  • Patent number: 6358994
    Abstract: This invention provides compounds of the Formula I: which are useful as tachykinin receptor antagonists. This invention also provides methods employing these compounds, as well as pharmaceutical formulations comprising these compounds.
    Type: Grant
    Filed: January 27, 2000
    Date of Patent: March 19, 2002
    Assignee: Eli Lilly and Company
    Inventors: James E Fritz, Philip A Hipskind, Stephen W Kaldor, Karen L Lobb, James A Nixon
  • Patent number: 6339094
    Abstract: This invention provides a series of substituted propanamines useful as tachykinin receptor antagonists. This invention also provides methods employing these substituted propanamines as well as pharmaceutical formulations comprising these compounds.
    Type: Grant
    Filed: January 27, 2000
    Date of Patent: January 15, 2002
    Assignee: Eli Lilly and Company
    Inventors: James E Fritz, Philip A Hipskind, Stephen W Kaldor, Karen L Lobb, James A Nixon
  • Patent number: 6245761
    Abstract: This invention provides a series of substituted indoles which are useful in treating or preventing a condition associated with an excess of neuropeptide Y. This invention also provides the novel substituted indoles as well as pharmaceutical formulations with comprise as an active ingredient one or more of these substituted indoles.
    Type: Grant
    Filed: August 29, 1996
    Date of Patent: June 12, 2001
    Assignee: Eli Lilly and Company
    Inventors: Thomas C. Britton, Robert F. Bruns, Jr., Donald R. Gehlert, Philip A. Hipskind, Karen L. Lobb, James A. Nixon, Paul L. Ornstein, Edward C. R. Smith, Hamideh Zarrinmayeh, Dennis M. Zimmerman
  • Patent number: 6175013
    Abstract: This invention provides a series of substituted 2-imidazolines which are useful in the treatment or prevention of a physiological disorder associated with an excess of tachykinins. This invention also provides methods for the treatment of such physiological disorders as well as pharmaceutical formulations which employ these compounds.
    Type: Grant
    Filed: June 10, 1994
    Date of Patent: January 16, 2001
    Assignee: Eli Lilly and Company
    Inventors: Philip A. Hipskind, J. Jeffry Howbert, Brian S. Muehl
  • Patent number: 5891875
    Abstract: This invention provides methods of treating a physiological disorder associated with an excess of tachykinins in a mammal which comprises administering to a mammal in need of said treatment a compound selected from a series of substituted morpholines. This invention also provides a series of novel substituted morpholines as well as pharmaceutical formulations employing these substituted morpholines.
    Type: Grant
    Filed: May 20, 1997
    Date of Patent: April 6, 1999
    Assignee: Eli Lilly and Company
    Inventors: Philip A. Hipskind, Karen L. Lobb
  • Patent number: 5792760
    Abstract: This invention provides a series of substituted bisindole propanamides which are useful as tachykinin receptor antagonists and as serotonin agonists. This invention also provides methods for the treatment of related disorders as well as pharmaceutical formulations which employ these novel compounds.
    Type: Grant
    Filed: April 23, 1997
    Date of Patent: August 11, 1998
    Assignee: Eli Lilly and Company
    Inventors: Philip A. Hipskind, Karen L. Lobb
  • Patent number: 5684033
    Abstract: This invention provides a novel series of non-peptidyl compounds which are useful in the treatment or prevention of a physiological disorder associated with an excess of tachykinins. This invention also provides methods for the treatment of such physiological disorders as well as pharmaceutical formulations which employ these novel compounds.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: November 4, 1997
    Assignee: Eli Lilly and Company
    Inventors: Sung Y. Cho, Thomas A. Crowell, Bruce D. Gitter, Philip A. Hipskind, J. Jeffry Howbert, Joseph H. Krushinski, Jr., Karen L. Lobb, Brian S. Muehl, James A. Nixon